Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ulocuplumab + LDAC in Newly Diagnosed AML
NCT02305563Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2015
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of ulocuplumab in acute myeloid leukemia (AML), sponsored by Bristol Myers Squibb. Started Jan 2015; status: terminated.
02
Drugs
ulocuplumab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02305563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02305563.